iTeos Therapeutics, Inc.
ITOS
$7.77
$0.273.60%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 9.43% | -43.08% | -40.69% | 79.22% | -145.75% |
| Total Depreciation and Amortization | 6.58% | 41.85% | 34.82% | 37.78% | 36.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.41% | -90.29% | 38.09% | 19.04% | 52.93% |
| Change in Net Operating Assets | -574.14% | 318.98% | 126.10% | -32,159.41% | 106.98% |
| Cash from Operations | -4.21% | 139.93% | -10.21% | -14.83% | -22.01% |
| Capital Expenditure | 89.31% | 89.11% | 87.48% | 36.86% | -694.12% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 169.61% | -78.13% | -489.85% | -19.42% | -117.43% |
| Cash from Investing | 168.52% | -77.88% | -503.16% | -18.81% | -119.60% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 45.45% | -10.75% | 360.00% | 56,035.78% | -96.19% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 45.45% | -7.17% | -4,520.00% | 56,035.78% | -96.19% |
| Foreign Exchange rate Adjustments | 117.97% | 2.48% | 316.20% | -358.04% | -44.21% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 113.79% | -60.94% | -954.03% | 1,246.52% | -75.86% |